Treats acquired immunodeficiency syndrome (AIDS). ANDA 207645, held by Pharmascience Inc. Ganciclovir Sodium.
As of Nov 16, 2026, ANDA 207645 (Ganciclovir Sodium), held by Pharmascience Inc, was first approved by FDA on Dec 8, 2017, with 2 approved supplements and 0 published complete response letters.
Ganciclovir Injection Ganciclovir Injection is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for the: treatment of CMV retinitis in immunocompromised adult patients, including patients with acquired immunodeficiency syndrome (AIDS). prevention of CMV disease in adult transplant recipients at risk for CMV disease. 1.1 Treatment of CMV Retinitis Ganciclovir Injection is indicated for the treatment of cytomegalovirus (CMV) retinitis in immunocompromised adult patients, including patients with acquired immunodeficiency syndrome (AIDS). 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 8, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ganciclovir SodiumEQ 500MG BASE/VIAL · injectable;injection | Ganciclovir Sodium | Rx |
| Feb 15, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| May 18, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Dec 8, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters